Focus: Tessera Therapeutics is a gene-writing biotech focused on rare diseases and gene therapy, headquartered in Somerville, MA. The company develops in vivo and ex vivo gene-editing therapies with emerging clinical validation.
Profile data last refreshed 8h ago · AI intelligence enriched 2mo ago
5 recent layoff filings (12 mo) — 168 affected
Source: state DOL filings via Big Local News
High-risk, high-reward opportunity best suited for scientists seeking cutting-edge gene-editing technology exposure, but job stability concerns and recent mass layoffs warrant caution.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Tessera Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Tessera Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Tessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive Officer - https://hrtoday.in/
Tessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive Officer https://hrtoday.in/
Tessera Therapeutics Inc - Reuters
Tessera Therapeutics Inc Reuters
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer - Business Wire
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer Business Wire
Sarepta names former AbbVie R&D exec Michael Severino as next CEO - BioSpace
Sarepta names former AbbVie R&D exec Michael Severino as next CEO BioSpace
Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chapter - Fierce Pharma
Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chapter Fierce Pharma
8-K Filing: Sarepta Therapeutics, Inc. (SRPT) (CIK 0000873303) — EX-99.1
EX-99.1
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Source: state DOL filings, aggregated via Big Local News
Recent large-scale layoffs signal financial distress or major strategy pivot; combined with new CEO appointment, suggests organizational instability over the next 12–18 months.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo